OSE Immunotherapeutics SA (0RAD.L)

5,48 -0,36 (-6,16%) In data: 09:08AM BST. Mercato aperto.

OSE Immunotherapeutics SA

22, boulevard Benoni Goulin
Nantes 44200
France
33 2 28 29 10 10
https://www.ose-immuno.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Nicolas Poirier Ph.D.	General Director, CEO, Scientific Director & Director	350,15k	N/D	1982
Ms. Anne-Laure Autret-Cornet	CFO, Administrative & Financial Director and Employee Shareholder Representative Director	N/D	N/D	N/D
Mr. Alexis Peyroles	Consultant	586,59k	N/D	1974
Dr. Alain Chatelin M.D.	Medical Director	N/D	N/D	N/D
Bérangère Vasseur M.D.	Chief Medical Officer Immuno-Oncology	N/D	N/D	N/D
Mr. Julien Perrier	Chief Commercial Officer	N/D	N/D	N/D
Ms. Linda Lebon M.Sc.	Chief Regulatory Officer	N/D	N/D	1967
Dr. Silvia Comis M.D.	Head of Clinical Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.

Governance aziendale

L'ISS Governance QualityScore di OSE Immunotherapeutics SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.